On January 5, 2018 NantWorks, the parent organization of NantHealth (NASDAQ: NH) and NantKwest (NASDAQ: NK) reported that Dr. Patrick Soon-Shiong (Chairman, CEO, and Founder) will present the current status of these companies and the overall ecosystem of NantWorks (Press release, NantKwest, JAN 5, 2018, http://ir.nantkwest.com/phoenix.zhtml?c=254059&p=RssLanding&cat=news&id=2325231 [SID1234522931]). Specific details will be presented regarding the current status of GPS CancerTM, including FDA filings and seminal patents issued covering tumor-normal analysis of DNA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, details will be presented regarding the record 25 letters of authorization covering 12 novel biological molecules tested across 20 tumor types within the NantWorks ecosystem of companies, of which 15 letters of authorization were received in 2017 for natural killer cells in combination with adenovirus, yeast, super agonist IL-15 and checkpoint inhibitors. The preliminary results of the first in human and safety studies of the NANT Cancer Vaccine will be released.

Presentation Time:

Time: January 9, 2018 at 5:00pm Pacific Time.
Location: 36th Annual J.P. Morgan Healthcare Conference – Elizabethan A/B Breakout: Sussex Room
Both the presentation and question and answer session that follows at 5:00pm will be webcast live at the below links and available for replay at both NantHealth and NantKwest.

NantWorks Presents at the 36th Annual J.P. Morgan Healthcare Conference
NantWorksQ & A Session at the 36th Annual J.P. Morgan Healthcare Conference